Key Stats for AbbVie Stock
- 52-Week Range: $164.4 to $244.8
- Current Price: $208.8
- Street High Target: $299
What Happened?
AbbVie (ABBV) entered 2026 having replaced nearly every dollar of Humira revenue it lost to biosimilars, posting record full-year net revenues of $61.2B on 8.6% growth while its two successor immunology drugs, Skyrizi and Rinvoq, together generated $25.9B and are already tracking $0.5B above the company’s own 2027 combined guidance, with shares sitting at $208.84 after pulling back from a 52-week high of $244.81.
The clearest trigger came on March 2, when AbbVie announced positive Phase 3 AFFIRM results showing Skyrizi’s subcutaneous injection formulation, a needle-based alternative to the current intravenous infusion that would remove a meaningful barrier to patient adoption, achieved 55% clinical remission and 44% endoscopic response at week 12 versus 30% and 14% for placebo, with the company immediately targeting a regulatory submission within months and U.S. approval as early as early 2027.
Skyrizi alone captured 75% of frontline new patient starts in inflammatory bowel disease, a chronic digestive condition representing one of the fastest-growing segments in specialty pharma, and its IBD revenues doubled year-over-year to $6.4B in 2025, a growth rate that far outpaces the high-single-digit market expansion and leaves Rinvoq, now label-updated in Q3 2025 to enter the second-line IBD setting without requiring prior anti-TNF failure, as an incremental revenue layer on top of an already-dominant position.
On the Q4 2025 earnings call, Chief Commercial Officer Jeffrey Stewart stated that Skyrizi’s in-play capture rate in frontline Crohn’s disease specifically reached 80%, directly reinforcing the commercial case for the subcutaneous formulation filing that would remove the IV infusion requirement holding back adoption.
AbbVie is guiding $67B in total revenues for 2026 at roughly 9.5% growth, projects free cash flow of $18.5B, expects its Parkinson’s and migraine franchises each to exceed $5B at peak, and holds no major patent cliffs before 2030, positioning the company for compounding high-single-digit revenue growth through at least 2029 while a pipeline spanning 90 active clinical programs, including the amylin obesity analog ABBV-295 that showed nearly 10% weight-loss delta in Phase 1 data disclosed March 10, and a psychedelic antidepressant bretisilocin approaching Phase 3, extends the growth runway well into the next decade.
Wall Street’s Take on ABBV Stock
The positive Phase 3 AFFIRM data for Skyrizi’s subcutaneous formulation, which removes the intravenous infusion requirement that currently limits patient access, directly changes the 2027 revenue trajectory and shifts the near-term growth narrative from recovery to acceleration.
TIKR estimates show normalized EPS jumping 45.4% to $14.54 in 2026, driven by Skyrizi and Rinvoq combined revenues reaching $31B, and EBITDA margins expanding from 40.0% in 2025 to 49.8% as operating leverage absorbs the Humira erosion that has now largely run its course.
Among 29 analysts covering ABBV, 22 carry buy or outperform ratings with a mean price target of $249.14, implying 19.3% upside from the current $208.84, reflecting confidence in the Skyrizi IBD volume ramp and the Rinvoq label expansion that opens the second-line gastrointestinal market without a prior anti-TNF requirement.
The $184 low target reflects concern that Botox Medicare pricing negotiations in 2028 and Imbruvica’s IRA-related pricing headwinds compress oncology revenue, while the $299 high target prices in a full Skyrizi subcutaneous label approval in early 2027 and lutikizumab Phase 3 success in hidradenitis suppurativa, a chronic skin disease with less than 5% biologic penetration.
What Does the Valuation Model Say?
The TIKR mid-case model prices ABBV at $325.24 by December 2030, implying a 9.8% annualized return, built on a 5.5% revenue CAGR and net income margins expanding to 41.6% as Skyrizi royalty obligations roll off and Vyalev, AbbVie’s 24-hour continuous Parkinson’s therapy, reaches the $1B blockbuster threshold guided for 2026.
At roughly 14.4x 2026 estimated EPS of $14.54, AbbVie trades at a meaningful discount to its own 5-year historical forward P/E range even as EPS growth is accelerating rather than decelerating, making ABBV stock undervalued relative to the earnings inflection the business is currently delivering.
Skyrizi’s 80% frontline Crohn’s disease capture rate and $6.4B IBD revenues already doubling year-over-year justify the TIKR model’s assumption of sustained high-single-digit revenue growth, supporting the $325.24 target as conservative rather than aggressive given 90 active clinical programs providing additional optionality.
Management’s explicit guidance that Skyrizi and Rinvoq combined will exceed $31B this year, already $0.5B above the company’s own 2027 target, signals the Street’s consensus still underestimates the pace of the immunology ramp.
If Skyrizi’s 75% frontline IBD share erodes materially following J&J’s oral psoriasis drug Icotyde expanding into bowel disease, the TIKR model’s 9.7% revenue growth assumption for 2026 breaks and the $325.24 target becomes unachievable.
Q1 2026 earnings on April 29 will confirm whether Skyrizi’s IBD capture rate held through the first quarter post-Icotyde approval, with the $4.4B Skyrizi quarterly guidance as the number to watch.
Should You Invest in AbbVie Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up ABBV stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track AbbVie Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze ABBV stock on TIKR for Free →
